Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single-blind pilot study

Arthritis and Rheumatism

Volumn 60, Issue 12, 2009, Pages 3821-3830

  Su, Tien I Karleen ^a   Khanna, Dinesh ^b   Furst, Daniel E ^b   Danovitch, Gabriel ^b   Burger, Christina ^b   Maranian, Paul ^b   Clements, Philip J ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; FENOFIBRATE; FOLIC ACID; HEMOGLOBIN; METHOTREXATE; RAPAMYCIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HEALTH ASSESSMENT QUESTIONNAIRE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFECTIOUS ARTHRITIS; KIDNEY DISEASE; LABORATORY TEST; LEUKOPENIA; MALE; MALNUTRITION; NAUSEA; OUTCOME ASSESSMENT; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SCLERODERMA; SCLERODERMA RENAL CRISIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WATERMELON STOMACH;

ADOLESCENT; ADULT; AGED; FEMALE; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; QUESTIONNAIRES; SCLERODERMA, DIFFUSE; SIROLIMUS; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73249139173     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24986     Document Type: Article

References (26)

1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-91.
2. Denton C. Therapeutic targets in systemic sclerosis. Arthritis Res Ther 2007;9 Suppl 2:S6.
3. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR/EUSTAR recommendations for the treatment of systemic sclerosis (SSc) [abstract]. Ann Rheum Dis 2007;66 Suppl 2:213.
4. Henness S, Wigley F. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr Opin Rheumatol 2007;19:611-8.
5. Van den Hoogen F, Boerbooms A, Swaak A, Rasker J, van Lier H, van de Putte L. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72.
6. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44: 1351-8.
7. Krishna Sumanth M, Sharma V, Khaitan B, Kapoor A, Tejasvi T. Evaluation of oral methotrexate in the treatment of systemic sclerosis. Int J Dermatol 2007;46:218-23.
8. Clements PJ, Lachenbruch PA, Sterz M, Danovitch G, Hawkins R, Ippoliti A, et al. Cyclosporine in systemic sclerosis: results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993;36:75-83.
9. US Food and Drug Administration. Rapamune. URL: http:// dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archived =1782.
10. Young D, Nickerson-Nutter C. mTOR: beyond transplantation [review]. Curr Opin Pharmacol 2005;5:418-23.
11. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001;72:1181-93.
12. Shegogue D, Trojanowska M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 2004;279: 23166-75.
13. Zhu J, Wu J, Frizell E, Liu SL, Bashey R, Rubin R, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999;117:1198-204.
14. Wyeth-Ayerst Research. Rapamune (sirolimus) maintenance regimen: summary for presentation to the subcommittee of the antiviral drugs advisory committee on immunosuppressive drugs. URL: http://www.fda.gov/ohrms/dockets/ac/02/ briefing/3832b1-01-Wyeth-Ayerst.pdf.
15. Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2983-8.
16. Nadiminti U, Arbiser JL. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol 2005;52 Suppl 1:17-9.
17. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
18. Danovitch GM. Handbook of kidney transplantation. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
19. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
20. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
21. Woodworth T, Furst DE, Alten R, Bingham C, Yocum D, Sloan V, et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol 2007;34:1401-14.
22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289: 2560-72.
23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
24. US Food and Drug Administration. The FDA Safety Information and Adverse Event Reporting Program. URL: http://www.fda.gov/ Safety/MedWatch/HowToReport/ ucm053087.htm.
25. Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006;65: 1325-9.
26. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203.